Recruiting NCT05851677
Disitamab Vedotin (RC48-ADC) in Breast Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Disitamab vedotin.
- Who it may be relevant to
- Registry conditions: Breast Cancer. Basic parameters: No limits · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Disitamab Vedotin (RC48-ADC) in Patients With Breast Cancer: a Real-world Study
Overview
To evaluate the efficacy and safety of Disitamab vedotin (RC48-ADC) in patients with breast cancer.
Interventions
- Drug Disitamab vedotin
recommended but not required regimen of 2.0mg/kg, iv, day1, every 2 weeks
Primary outcome measures
- Progression-Free Survival [Time frame: From the date of starting Disitamab vedotin to the date of first documentation of progression or death (up to approximately 1 years)]
Secondary outcome measures (1)
- Adverse events [Time frame: From the date of starting Disitamab vedotin to the end of the treatment (up to approximately 1 year)]
Eligibility criteria
Inclusion criteria
- Histologically confirmed breast cancer;
- Prior or current use of Disitamab vedotin (RC48-ADC);
Exclusion criteria
- Participating in clinical trials involving Disitamab vedotin (RC48-ADC) or not.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Cohort
Study locations
China · 1 center
- Renji Hospital, School of Medicine, Shanghai Jiaotong University — Shanghai
Identifiers
NCT: NCT05851677 · LY2023-062-B